Search company, investor...

Nitrase Therapeutics

Founded Year



Grant | Alive

Total Raised


About Nitrase Therapeutics

Nitrase Therapeutics is a biopharmaceutical company that manages to deploy its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes discovered in-house that offers the promise of a pipeline of therapies against a broad variety of diseases. It discovers and develops novel medicines for diseases in which nitrases and nitro-substrates play a role and are initially focused on Parkinson’s disease, but nitrases and their nitro-substrates are also implicated in other neurodegenerative diseases, fibrotic diseases, respiratory diseases, autoimmune diseases, and cancer. It is based in Brisbane, California.

Headquarters Location

1000 Marina Blvd,

Brisbane, California, 94005,

United States

Missing: Nitrase Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nitrase Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nitrase Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nitrase Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Nitrase Therapeutics News

HitGen Announces Research Agreement With Nitrase Therapeutics Focused On DNA-Encoded Library Based Drug Discovery

Dec 15, 2022

Chengdu /PRNewswire/ - Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases. Nitrases have been implicated in numerous devastating diseases, including Parkinson's, cancer, respiratory diseases, fibrosis and other neurodegenerative diseases. Nitrase's NITROME platform has generated leads for the inhibition of nitrase enzymatic reactions that can cause disease, and is developing drugs based on the newly discovered role that protein nitration plays in disease. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of DELs to discover compounds that bind to certain targets that are of interest to Nitrase. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Nitrase. HitGen is a world leader in the development of the DEL technology and applications to early-stage small molecule drug discovery. The availability of over 1.2 trillion small molecules generated by the DEL technology and the efficiency of the screening process have made it possible for HitGen to enable drug discovery projects for many organizations around the world. Nitrase Therapeutics has made breakthrough discoveries in the role of protein nitration, caused by company-discovered enzymes called nitrases, in various diseases," said Pierre Beaurang, Ph.D., Chief Executive Officer of Nitrase Therapeutics. "We have identified over 30 nitrases thus far, and we look forward to working with HitGen to expand our existing pipeline of compounds that are capable of modulating nitration for the development of novel therapeutics." "It's really exciting for us to work on this novel target class with Nitrase. As one of HitGen's four core technology platforms, DEL is an efficient 'engine' to advance drug discovery. We look forward to working closely with Nitrase's scientists to identify novel hits from HitGen's DNA-encoded libraries and generate new lead compounds for their research programs to address unmet medical needs associated with Parkinson's and other diseases," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen. About Nitrase Therapeutics, Inc. Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad range of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of numerous diseases in which nitrases and nitro-substrates play a role, including Parkinson's, cancer, immunological and fibrotic diseases. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Nitrase Therapeutics is located in Brisbane, CA, and its investors include Sofinnova Partners, AbbVie Ventures, Dementia Discovery Fund, Bristol Myers Squibb, Mission Bay Capital and Alexandria Venture Investments. For more information, please visit the company's website at . About HitGen Inc. HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage. For more information, visit . For media inquiries:

Nitrase Therapeutics Frequently Asked Questions (FAQ)

  • When was Nitrase Therapeutics founded?

    Nitrase Therapeutics was founded in 2017.

  • Where is Nitrase Therapeutics's headquarters?

    Nitrase Therapeutics's headquarters is located at 1000 Marina Blvd,, Brisbane.

  • What is Nitrase Therapeutics's latest funding round?

    Nitrase Therapeutics's latest funding round is Grant.

  • How much did Nitrase Therapeutics raise?

    Nitrase Therapeutics raised a total of $45.9M.

  • Who are the investors of Nitrase Therapeutics?

    Investors of Nitrase Therapeutics include The Michael J. Fox Foundation, Bristol-Myers Squibb, Sofinnova Partners, Dementia Discovery Fund, Alexandria Venture Investments and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.